NEOPREDIX B.1
Empowering clinical decision
making for jaundice
The NeoPrediX B.1 solution transforms clinical data into scientifically validated forecasts to improve the speed and accuracy of clinical decisions.
NeoPrediX B.1. Built by clinicians and data scientists, our solution is used to
anticipate and mitigate the risk of jaundice in newborns. Support clinical decision
making, improve patient safety, and automate bilirubin predictions using the Neo-
PrediX web application.
- Individualize and optimize quality of care for each newborn
- Monitor bilirubin progression to replace readmissions with scheduled visits
- Identify patients at-risk for jaundice for more confident discharge decisions
- Standardize care with an algorithm backed by a multi-site clinical trial
- Improve workflows and efficiency to decrease clinician burnout
PRODUCTFEATURES
Key capabilities of NeoPredix B.1
- Forecasts bilirubin progression with just a few standard clinical values
- User friendly web application
- Shows bilirubin forecast and treatment threshold
- Forecasts up to 60 hours with just two TSB serum measures or three TCB levels
- Incorporates new AAP 2022 guidelines for managing hyperbilirubinemia
- Displays relevant historical patient data
- Generates formatted PDF reports
The NeoPrediX B.1 web application
ADVANTAGES
Can your jaundice care app do this?
While existing online tools make automated care recommendations and plot bilirubin levels, the advantages of NeoPrediX B.1 are:
- Scientifically validated technology forecasts 60 hours of dynamic bilirubin progression
- Available for full EMR integration or as a stand-alone application
- Proprietary algorithm backed by a multi-site clinical trial
- Incorporates the significance of TSB vs TCB tests
- Captures historic patient data to highlight trends over time
These and many other capabilities put greater expertise in the hands of clinicians to accurately forecast dynamic bilirubin progression
Bringing validated forecasts to the newborn nursery
Healthcare Professionals
- Forecast bilirubin progression with assurance
- Expertise-at-your-fingertips with a proven algorithm
- Improved patient safety with rapid identification of jaundice risk
- Scientifically validated automation of an essential newborn assessment
Supervisors and Administrators
- Standardize decision making around newborn discharge
- Avoidance of unplanned readmissions
- Staff efficiency and department cost effectiveness
- Decrease clinician burnout and improve patient-family satisfaction
IT / Operations
- Intuitive ready-to-use web application
- GDPR- and HIPAA-compliant with standards of data integrity and protection
- Available for full EMR integration or as a stand-alone application
5M+
births per year
in Europe
6 OUT
OF 10
babies develop
jaundice
40 %
babies need
phototherapy
>€100M
annual savings potential due to
optimized length of stay based on prediction of bilirubin levels
VALIDATION
Clinically valid application
- Solution validated by a multi-site clinical study
- Incorporates relevant patient data such as risk factors and diagnoses
- Algorithm fortified by population data from 15,000 newborns
- Bilirubin forecasts improve discharge care planning
CONNECT WITH US
Learn more about NeoPredix B.1
by contacting us
NeoPrediX AG (Switzerland)
Aeschengraben 20, 4051 Basel, Switzerland
Executive Team: Jörg Schmidt, Prof. Dr. Marc Pfister , Prof. Dr. Sven Wellmann
Registered office: Basel
Commercial register number CH-270.3.016.001-3
Chairman of the board: Dr. Gerhard Ries
NeoPrediX USA, Inc. (US)
110 E Broward Blvd #1700
Fort Lauderdale, FL 33301, United States
Phone: +1 (954)-315-3884
NeoPrediX AG (Germany)
Franz-Mayer-Straße 1, 93053 Regensburg
Excecutive Board: Thorsten Waloschek (chairman), Jörg Schmidt
Registered Office: Regensburg
Commercial register number: HRB 18679
Supervisory Board: Dr. Volker Pfahlert (chairman), Arne Kirchner, Prof. Dr. Marc Pfister, Dr. Gerhard Ries, Prof. Dr. Sven Wellmann
